liver cirrhosis with diabetes
Conditions
Interventions
observation group:Semaglutide 0.25mg, Qw start, step up to 1.0mg, Qw maintenance therapy
Control group 1 :Do not use semaglutide treatment, maintain the original hypoglycemic treatment regimen
Control group 2:Semaglutide 0.25mg, Qw start, step up to 1.0mg, Qw maintenance therapy
Control group 3:Do not use semaglutide treatment, maintain the original hypoglycemic treatment regimen
Sponsors
Beijing You'an Hospital ,Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 18 = age < 65 years old, gender is not limited Clinical or pathological diagnosis of liver cirrhosis Child-Pugh A or B 7 points Definitely diagnosed as type 2 diabetes No anemia, HbA1c = 8.0% Newly diagnosed drug-free or hypoglycemic drugs have not been adjusted in the past 90 days, poor blood sugar control, need to use or switch to semaglutide Sign the informed consent
Exclusion criteria
Exclusion criteria: Family or personal history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma. Dependents are defined as first-degree relatives acute or chronic pancreatitis Existence or history of malignancy within 5 years prior to screening merged HIV History of diabetic ketoacidosis Myocardial infarction, stroke, unstable angina, or transient ischemic attack Coronary, carotid, or peripheral arterial revascularization eGFR less than 60ml/min/1.73m2 pregnancy Other patients considered unsuitable for this study by doctors, such as other serious diseases affecting nutritional status
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| L3-SMI;Blood glucose control; | — |
Countries
China
Contacts
Public ContactZhang Jing
Beijing You'an Hospital ,Capital Medical University
Outcome results
None listed